

Chicago Specials

Fall Group Meeting

OCTOBER 8 - 10, 2026



Immunotherapeutics Committee

Immunotherapeutics Committee

Leadership

Co-Chairs: Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 Matt Chansky, BS

Designates

Data Coordinators: Michele Counts
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Robin Kamucheka
 Clinical Trial Program Manager: Sharon Palmer

Time/Location

Friday, October 9, 2026 9:00 a.m. - 11:00 a.m.
 Room: Water Tower (Concourse Level)

Agenda

9:00 – 9:05 am	Welcome & Immunotherapeutics Committee Update Siwen Hu-Lieskovan & Katerina Politi <i>SWOG Immunotherapeutics Committee Co-Chairs</i>
9:05 – 9:20 am	iMATCH Pilot Update: Stage II Update Siwen Hu-Lieskovan, Katerina Politi, Paul Swiecicki <i>S2101 Study Chairs</i>
9:20 – 9:25 am	Q & A
9:25 – 9:40 am	Immunotherapeutic Strategies in Small Cell Lung Cancer - Anne Chi-An Chiang, MD, PhD <i>Executive Officer, Immunotherapeutics</i> <i>Associate Cancer Center Director, Yale School of Medicine</i>
9:40 – 9:50 am	Q & A
9:50 – 10:15 am	Second Talk TBD
10:15 – 10:25 am	Alliance Immunotherapeutics Update Elad Sharon, MD, MPH <i>Associate Professor of Medicine</i> <i>Dana-Farber Cancer Institute</i>
10:25 – 10:35 am	ECOG-ACRIN Immunotherapeutics Update Yana G. Najjar, MD <i>Associate Professor of Medicine, University of Pittsburgh</i> <i>Director, Clinical and Translational Research Center</i>

10:35– 10:50 am	Cancer Immune Monitoring and Analysis Center (CIMAC) Update - Cara Haymaker, PhD <i>Associate Professor, University of Texas MD Anderson Cancer Center, MDA CIMAC Co-Lead</i>
10:45 – 10:55 am	Panel Discussion
10:55 – 11:00 am	Final Comments & Closing Remarks Siwen Hu-Lieskovan & Katerina Politi <i>SWOG Immunotherapeutics Committee Co-Chairs</i>

Active Studies

S2101, "Biomarker Stratified CaboZantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Publications

The publication papers listed below from 2026 have not appeared as published in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

None this cycle.

Submitted Manuscripts

None this cycle.

Immunotherapeutics Committee

Accrual from trials that are open as of 6/30/2026 or have closed in the prior 18 months, by Institution and Study

	<i>S2101</i>
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	<i>1</i>
<i>Essentia Health NCI Community Oncology Research Program</i>	<i>1</i>
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	<i>5</i>
<i>Heartland Cancer Research NCORP</i>	<i>1</i>
<i>Michigan Cancer Research Consortium NCORP</i>	<i>1</i>
<i>Northwestern University LAPS</i>	<i>2</i>
<i>Pacific Cancer Research Consortium NCORP</i>	<i>1</i>
<i>Regents of the University of Michigan</i>	<i>16</i>
<i>The NCI Community Oncology Research Program: The New Mexico NCORP</i>	<i>1</i>
<i>UC Irvine Health/Chao Family Comprehensive Cancer Center</i>	<i>6</i>
<i>University of Arkansas for Medical Sciences</i>	<i>5</i>
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	<i>12</i>
<i>ALLIANCE</i>	<i>22</i>
<i>ECOG-ACRIN</i>	<i>15</i>
<i>NRG</i>	<i>12</i>
<i>Total</i>	<i>101</i>

